Clin Mol Hepatol.
2020 Oct;26(4):582-583. 10.3350/cmh.2020.0264.
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
- Affiliations
-
- 1Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
- 2Veterans Affairs Medical Center, George Washington University, Washington, D.C, WA, USA
- KMID: 2507977
- DOI: http://doi.org/10.3350/cmh.2020.0264
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- KASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease
- Should you advocate for hepatocellular carcinomasurveillance in patients with alcohol-related liverdisease or non-alcoholic fatty liver disease?
- Clinical impact of nonalcoholic fatty liver disease on other medical diseases
- Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development
- How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
